GLP-1 Costs by Dose: Does Titrating Up Actually Cost More?

Sometimes. It depends which of four completely different pricing philosophies your seller has adopted — and, separately, on whether a higher dose costs anyone anything more to supply. Those two questions have different answers, and the gap between them is the interesting part.

Philosophy one: flat at every dose

The price does not move, whatever strength you are on.

Mounjaro® on LillyDirect — "Starting at $499/month", printed against all six strengths from 2.5 mg to 15 mg.¹

Found — one plan price covering compounded medication at any dose, $289 a month on the month-to-month rate.²

Zealthy — $297 a month for its semaglutide bundle and $449 for its tirzepatide bundle, flat.³

Strut Health — $99 for compounded oral semaglutide, $149 for the injectable, with no dose ladder published.⁴

On these products, titrating is free. Your annual number is set on day one.

Philosophy two: a rising ladder

The price climbs step by step, then flattens.

Zepbound® on LillyDirect — $299 at 2.5 mg, $399 at 5 mg, $449 at 7.5, 10, 12.5 and 15 mg.⁵

Foundayo™ on LillyDirect — $149 at 0.8 mg, $199 at 2.5 mg, $299 at 5.5 mg and above.⁶

Wegovy® tablets on NovoCare — $149 at 1.5 mg, $149 at 4 mg until 31 August 2026 then $199, $299 at 9 mg and 25 mg.⁷

Ozempic® tablets — $149 at 1.5 mg, $199 at 4 mg, $299 at 9 mg.⁸

Three of those four ladders have the same shape: a cheap first step, a second step, then a plateau. The plateau is where you will actually live.

Philosophy three: flat, then one jump at the top

The most easily missed shape, because it looks flat until it isn't.

Wegovy pens — $349 at 0.25, 0.5, 1, 1.7 and 2.4 mg, then $399 for the 7.2 mg high-dose pen.⁷

Ozempic pens — $349 at 0.25, 0.5 and 1 mg, then $499 at 2 mg.⁸

The Ozempic jump is the sharp one: a 43% increase at a single step, and it lands exactly where the price meets Mounjaro's flat $499.

Philosophy four: conditional on the calendar

Lilly attaches a refill condition to the Zepbound and Foundayo ladders. The published prices hold on a refill within 45 days of the last delivery; outside the window, Lilly's regular prices apply — $499 to $699 for Zepbound, and $349 rather than $299 for Foundayo's top two tiers.⁵

Ro, which resells branded Zepbound, prints the same ladder in detail on its own page: $499 at 7.5 mg and $699 from 10 mg upward if the refill check-in is late, against $449 either way if it is on time.⁹

So the same dose has two prices, and which one you get is decided by a date.

Does a higher dose cost anyone more to supply?

This is the question nobody asks, and CMS publishes the answer. NADAC surveys what retail pharmacies pay wholesalers. On the file dated 5 August 2026, rates effective 22 July¹⁰, per month of supply:

Ozempic pens — $995.90 at 0.25/0.5 mg, $995.68 at 1 mg, $995.81 at 2 mg. A spread of 22 cents across a ladder that charges patients $349 to $499.

Wegovy pens — $1,306.77 at 0.25 mg, $1,306.72 at 2.4 mg. A spread of five cents.

Mounjaro pens — $1,077.21 at 10 mg, $1,076.92 at 15 mg. 29 cents.

Zepbound single-dose pens — $1,052.55 at 2.5 mg, $1,052.30 at 10 mg. 25 cents.

Wegovy tablets — $1,305.28 for 30 days at 1.5 mg, $1,301.50 at 25 mg. The highest dose is the *cheapest* to acquire.

In every one of those cases, a milligram of extra drug costs the supply chain essentially nothing. The patient-facing ladder is a commercial structure laid over a flat line.

The one place where it genuinely does

There is a single exception in the data, and it is a big one.

Zepbound KwikPen, 5 mg per dose — $201.45456 per mL × 2.4 mL = $483.49.

Zepbound KwikPen, 10 mg per dose — $281.30588 × 2.4 = $675.13.

That is a 39.6% step at 10 mg, in a device where the higher-strength version really does contain proportionally more drug in the same 2.4 mL.

Now put Lilly's own late-refill ladder beside it: $499 at 7.5 mg, $699 from 10 mg. A 40.1% step, at the same dose.

Two numbers computed from two unrelated sources — a CMS acquisition survey and a manufacturer's published regular price — landing within half a percentage point of each other. It is the only place in this market where a dose-based price step appears to track a real cost step.

What this means for a titration budget

Three practical consequences.

On a flat-priced product, titration is free and your annual figure is fixed from the first fill. On a laddered one, the fastest escalation the label allows is also the most expensive path to the plateau — but only slightly. Zepbound escalating one step per fill to 10 mg over 13 fills is $299 + $399 + $449 + (10 × $449) = $5,637, against $5,837 for thirteen fills at $449 flat. Titration saves $200.

And the plateau is what you are actually buying. Every ladder in this market flattens within three or four steps, so the entry price is the least informative number on the page. What happens at the top is covered in what happens to your price at maintenance.

What we could not price

We could not verify a NADAC line for the Wegovy HD 7.2 mg pen at the 22 July effective date — the figure we found carries a 17 June date — so the high-dose pen is absent from the acquisition comparison.

We could not find a NADAC line for the Zepbound single-dose vial or for the Foundayo tablet in the 5 August file, so neither appears in the supply-cost section.

And we could not price any dose through insurance, because plan-level cost sharing is not published per drug by any first-party source.

Related: Mounjaro vs Ozempic on price, what LillyDirect costs, and the compounded flat-price sellers on the compounded tirzepatide board.

Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound® and Foundayo™ are trademarks of Eli Lilly and Company.